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Quinoxaline-2, 3-dione obtained from cyclocondensation reaction of o-phenylene diamine with oxalic acid was reacted with
three diﬀerent ketones and formaldehyde to give the corresponding Mannich bases in satisfactory yield. Their structures were
conﬁrmed by using 1H NMR, IR, and mass analysis. In pharmacological evaluation, the synthesized compounds showed its
curativeeﬀectagainstethidium-bromide-induceddemyelinationinrats.Forthepurpose,diﬀerentscreeningmethodssuchasopen
ﬁeldexploratorybehaviortest,rotarodtest,gripstrengthtest,beamwalktest,andphotoactometertestwereperformed.Ethidium
bromide induction showed muscle weakness; muscle discoordination; loss of locomotor activity, and so forth, the synthesized
drugs reversed all the above-mentioned neuromuscular disorders caused by ethidium bromide administration.
1.Introduction
Quinoxaline-2, 3-dione derivatives are important classes of
nitrogen-containing heterocycles, as they constitute useful
intermediates in organic synthesis [1]. In particular, quinox-
aline scaﬀolds were found as a core unit in a number of
biologically active compounds. Quinoxaline including their
fused ring derivatives display diverse pharmacological activi-
ties such as neuroprotective agents, antifungal, antibacterial,
radio protective, anticonvulsant, antimalarial, anticancer,
potent antithrombotic, analgesic, anti-inﬂammatory, anti-
glaucoma,antiparasite,antituberculosis,hypoglycemic,anti-
viral, anti-HIV, anthelmintic activities, antidepressant,
NMDAreceptorantagonist,andantimalarialactivities[2–5].
Among the glutamate receptor antagonists, AMPA-R anta-
gonists appear to be free from side eﬀects such as schiz-
ophrenia and have shown eﬀectiveness against neuronal
death, even if administered after-ischemia. In consequence,
AMPA-R antagonists have been reported to be eﬀective in
the therapy of neurodegenerative disorders such as ischemic
stroke, epilepsy, head trauma, and Alzheimer’s disease [6, 7].
In the literature are described diﬀerent series of AMPA
receptor antagonistic, one of which is based on the
quinoxaline-2, 3-dione structure, which have high aﬃnity
and selectivity. Typical examples are
(1) 7-nitro-2, 3-dioxo-1, 2, 3, 4-tetrahydroquinoxaline-
6-carbonitrile (CNXQ),
(2) 6-(1H-imidazol-1-yl)-7-nitro-1, 4-dihydroquinoxa-
line-2, 3-dione (YM90K),
(3) [7-(1H-imidazol-1-yl)-6-nitro-2,3-dioxo-3,4-dihydro-
quinoxaline-1(2H)-yl] acetic acid (YM872),
(4) 1-[4-(carboxymethyl)-7-nitro-2, 3-dioxo-1,2,3,4-tet-
raquinoxaline-6-yl]-1Hpyrrole-3-carboxylic acid
(Lu123313),
(5) 6-nitro-2,3-dioxo-1,2,3,4-tetrahydrobenzo [f] quin-
oxaline-7-sulphonamide (NBXQ),
(6) 9-(1H–imidazol-1-yl)-8-nitropyrazolo [1,5-c]quin-
azoline-2,5(3H,6H)-dione (RO-48-8587).
These compounds are screened for neuropharmacologi-
cal activity in mice and rats (analgesia, sedation, convulsion,
anxiety, memory, and psychosis) (Scheme 1).2 The Scientiﬁc World Journal
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Scheme 1: Diﬀerent AMPA receptor antagonists.
The available AMPA antagonistic compounds such as
6-cyano-7-nitroquinoxaline-2, 3-dione (CNQX), 6, 7-din-
itroquinoxalone-2, 3-dione (DNQX), or earlier compounds
such as glutamic acid diethyl ester (GDEE) had very little
antagonist activity in vivo due to their lack of aﬃnity.
Since these compounds are based on quinoxaline-2, 3-
dione, we were planning to synthesize some novel quinoxa-
line dione derivatives and to evaluate their antagonistic ac-
tion through neuroprotection.
2. Results and Discussion
2.1. Chemistry. The synthetic route followed for obtaining
compounds (2a–c) are outlined in Scheme 2.T h u s ,c y c l o -
condensation of o-phenylene diamine (1) with oxalic acid
in presence of hydrochloric acid aﬀorded quinoxaline 2, 3-
dione (2) by both conventional and microwave irradiation
method. In microwave method, the percentage yield was
higher than the conventional method. The NH groups ofThe Scientiﬁc World Journal 3
NH2
NH2
+
COOH
COOH
N
H
H
N
O
1 2
N
2a-c
O
N
O
O
b
a + R1COCH3
CH2CH2COR
CH2CH2COR
R-CH3, C2H5, CH3COCH2
Scheme 2: Synthesis of the compounds; reagents and conditions; (a) reﬂux on an oil bath, 1.5h; (b) 40% HCHO, R1COCH3,D M F ,s t i r ,6h .
compound 2 were undergone Mannich reaction with diﬀer-
ent ketones, and formaldehyde aﬀorded the Mannich bases
(2a–c). The percentage yield was 50–85%. The synthesized
compounds were checked for their purity through melting
point determination and TLC. Further, all the compounds
w e r ec h a r a c t e r i z e db ys p e c t r a la n a l y s e ss u c ha sI R ,1HN M R ,
and mass spectra. The data are consistent with the assigned
structures.
2.2. Pharmacology. The synthesized compounds, com-
pounds 2a, 2b,a n d2c were screened for neuroprotective ac-
tivity. Before induction of demyelinating lesions to the
animals, acute toxicity study was carried out to ﬁnd out
the doses. Most demyelination of CNS produces diﬃculty in
locomotorandbehavioralpattern.Symptomsareconfusion,
muscle weakness, numbness, muscle discoordination, and
hind limb paralysis. Hence, the following animal tests were
carried out to assess the introduction and to evaluate the re-
myelination in animals. The tests are
(i) open-ﬁeld exploratory behavior test,
(ii) rotarod test,
(iii) gripstrength test,
(iv) beam walk test,
(v) photoactometer test.
The animals subjected for the above tests were observed
for four weeks except for open-ﬁeld exploratory behaviour
test, which was carried out for only one week. The results
obtained are as follows.
2.2.1. Open-Field Exploratory Test. From this study, it was
found that ethidium-bromide-treated group showed de-
creased locomotor activity at the end of the ﬁrst week.
Among the synthesized quinoxaline-2, 3-dione, 2c showed
the highest activity with increased in ambulation and
decreased freezing time with that of ethidium-bromide-in-
duced groups. It indicated that due to the induction of dose
of the synthesized compounds, there was an alteration in
ethidium-bromide-induced toxic locomotor eﬀect. The re-
sults are given in Table 1.
2.2.2. Grip Strength Test. The experiment was carried out
to measure the muscle coordination and strength, when
the animals were put in the wire mesh. The time taken
to catch the wire and the time spent on the mesh by
holding the wire were measured. Ethidium-bromide-treated
animals took more time to catch the wire with their hind
legs, and the time spent on the wire by holding position
was also was very little. These results clearly indicate the
administration of the toxic ethidium bromide resulted in
decreased muscle coordination and grip strength. It may be
due to demyelination of nerve ﬁbres leading to the impaired
conduction of nerve impulses. Treatment of animals with 2a,
2b,a n d2c reversed the observed grip strength deﬁcit. The
results are given in Table 2.
2.2.3. Rota Rod Test. To analyse the muscle coordination,
rota rod test was performed. The results indicated the
ethidium bromide treated rats took very short time to fall
from the rota rod apparatus, indicating the loss of muscle
coordination. At the end of the fourth week, rats treated with
the synthesized compounds spent increased time on the rota
rod, indicating the muscle coordination had been recovered
as that of the control group. The synthesized compounds
showed little higher eﬀects at the end of fourth week than
standard drug. The results are given in Table 3.
2.2.4. Beam Walk Test. This is used to evaluate the activity of
the drugs interfering with motor coordination. In this test,
the ability of the animal to walk on the beam was evaluated.
It had been observed that ethidium bromide treated animals
walkedlessdistanceandfallingtimewasalsolesscomparable
to control group.4 The Scientiﬁc World Journal
Table 1: Open-ﬁeld exploratory test.
Groups Ambulation Rearing Fecal pellets Freezing time
Control 133.7 ±0.6667 19.53 ±0.2186 0.7 ±0.3930 51.53 ±0.1453
Ethidium
Bromide 87.67 ±6.960 13.0 ±1.155∗ 3 ±0.5774∗ 68.53 ±0.2028
Antioxidant 108.2 ±2.083∗∗∗ 25.2 ±1.530∗∗ 3.8 ±0.2000∗∗ 58.48 ±0.675∗∗∗
Comp2a 115.8 ±0.3742∗∗ 26.4 ±0.050∗∗ 3.2 ±0.489 40.50 ±0.5117∗∗∗
Comp2b 109.4 ±0.335∗∗∗ 33.6 ±0.743∗∗∗ 3 ±0.5477∗∗ 43.46 ±0.1536∗∗∗
Comp2c 153.4 ±0.6000∗∗∗ 39.42 ±0.159∗∗∗ 3.6 ±0.6782∗∗ 46.28 ±0.1020∗∗∗
P<0.05; ∗∗∗extremely signiﬁcant; ∗∗moderately signiﬁcant; ∗signiﬁcant.
Table 2: Grip strength test.
Groups Time taken to catch the
wire with hind limb
Total time the animal
catches the wire Falling time Fecal pellets
Control 8.567 ±0.0333 186.7 ±0.028 92.6 ±0.881 1 ±0
Ethidium
Bromide 4.3 ±0.100 143.0 ±0.603∗∗∗ 124.7 ± 0.480∗∗∗ 4.3 ±0.333∗∗∗
Antioxidant 3.740 ±0.0748∗∗∗ 154 ±1.140∗∗∗ 104.8 ± 0.985∗∗∗ 3 ±0.3162∗∗
Comp2a 3.320 ±0.2354∗∗ 151.2 ±0.274∗∗ 99.20 ±0.020∗ 2.6 ±0.2449∗
Comp2b 3.2 ± 0.05477∗∗∗ 148.4 ±0.707∗∗∗ 105 ± 0.707∗ 4.750 ±0.478∗∗
Comp2c 1.68 ±0.1068∗∗ 161.4 ±0.534∗ 101.8 ±0.916∗∗ 3.4 ±0.4∗∗∗
P<0.05; ∗∗∗extremely signiﬁcant; ∗∗moderately signiﬁcant; ∗signiﬁcant.
Table 3: Rota rod test.
Groups Falling time Fecal pellets
Control 311.7 ±0.6667 4 ±0.5774
Ethidium
Bromide 113.7 ± 0.8819∗∗∗ 1.6 ±0.333∗∗∗
Antioxidant 188 ±1.095∗∗∗ 2.2 ±0.2∗∗∗
Comp2a 203.2 ± 0.9695∗∗∗ 1.8 ±0.2∗∗∗
Comp2b 177.2 ±1.562∗∗∗ 2.8 ±0.3742∗
Comp2c 212.2 ± 0.9695∗∗∗ 1.8 ±0.2∗∗∗
P<0.05; ∗∗∗extremely signiﬁcant; ∗∗moderately signiﬁcant; ∗signiﬁcant.
Rats treated with the compounds 2a, 2b,a n d2c, at the
end of fourth week, increased distance of walk on the beam
and falling time, indicating the muscle coordination had
been recovered as that of the control group. The synthesized
compounds showed moderate activity when comparable to
the standard. The results are given in Table 4.
2.2.5. Photoactometer Test. To study the locomotor activity
(CNS-depressant activity) of ethidium bromide and its re-
covery by means of synthesized drugs on rats, photoac-
tometer was mainly used. The animals subjected for this
test were observed for the 1st, 2nd, and 4th week. The
results clearly indicated that the ethidium-bromide-treated
rats moved lesser square-shaped space of the instrument at
the end of the 1st week, and the same was maintained at the
e n do ff o u r - w e e kp e r i o d .
Treatment of animals with the selected doses of syn-
thesized drugs in the above tests signiﬁcantly increased the
observed locomotor activity which was comparable to that
of the control group. The compounds 2a, 2b, and 2c showed
greater activity than the standard. The results are given in
Table 5.
2.3.HistopathologicalStudies. Thedemyelinationinducedby
ethidium bromide on rats and remyelination by synthesized
drugs were conﬁrmed by the histopathological studies. The
midbrainsectionofthebrainwasstainedwithLuxolfastblue
to study the neurodegeneration eﬀects of EB and protective
eﬀect of standard and synthesized drugs 2a, 2b, and 2c
in the midbrain region. The eﬀect of ethidium bromide,
dose of 10μL solution of 0.1% ethidium bromide and
synthesized drugs in the dose of 20mg/kg body weight on
ratswereshown(Figures1and6).Themyelinatedﬁbreswere
visualized as blue in colour, neutrophils in pink, and nerve
cells in purple.
The midbrain regions of control rats were found to be
intact, and no destruction of the myelin sheath was ob-
served (Figure 1). There is loss of myelinated ﬁbres in the EB
induced rats (Figure 2). It demonstrated distinct degenera-
tion of myelin sheath indicating neurotoxicity. Administra-
tion of standard drug and synthesized drugs (2a, 2b, and 2c)
on rats accelerated the myelin regeneration (Figures 3, 4, 5
and 6).
3. Conclusion
In pharmacological evaluation, the selected synthesized
drugs showed their curative eﬀect against intracranially
administered ethidium-bromide-induced demyelination inThe Scientiﬁc World Journal 5
Table 4: Beam walk test.
Groups Distance walked Total time taken to walk Falling time Fecal pellets
Control 209.5 ±0.2082 300 127.6 ±0.057 1 ±0
Ethidium
Bromide 35.47 ±0.2906 300 166.5 ±0.29∗∗ 5.76 ±0.39∗∗
Antioxidant 171.6 ±0.7928∗∗∗ 300 142.8 ±0.58∗∗ 1.6 ±0.24∗∗∗
Comp2a 142.5 ±0.1435∗∗∗ 300 111.4 ±0.170∗ 1.4 ±0.24∗∗∗
Comp2b 158.4 ±0.147∗∗∗ 300 92.3 ±0.803∗∗∗ 1.2 ±0.2∗∗∗
Comp2c 137.4 ±0.12.8∗∗∗ 300 118.3 ±0.0816∗∗∗ 1.6 ±0.24∗∗∗
P<0.05; ∗∗∗extremely signiﬁcant; ∗∗moderately signiﬁcant; ∗signiﬁcant.
Table 5: Photoactometer test.
Groups Time of movement
(sec)
Counts of
movements
Control 600 283.3 ±1.202
Ethidium bromide 600 149.0 ±2.082∗∗∗
Antioxidant 600 215.2 ±1.2∗∗∗
Comp 2a 600 257.2 ±1.158∗∗∗
Comp2b 600 249.1 ±0.678∗∗∗
Comp2c 600 232.8 ±1.241∗∗∗
P<0.05; ∗∗∗extremely signiﬁcant; ∗∗moderately signiﬁcant; ∗signiﬁcant.
Figure 1: High-magniﬁcation photomicrographs of LFB-stained
midbrain sections from normal control group.
rats. For the purpose, diﬀerent screening methods such
as open-ﬁeld exploratory behavior test, rota rod test, grip
strength test, beam walk test, and photoactometer test were
performed. Ethidium-bromide-induction showed muscle
weakness;muscleincoordination;lossoflocomotoractivity,
and so forth the selected synthesized drugs reversed all the
above said disorders developed as a result of ethidium-bro-
mide-induction.
Hence from the above results, it was established that the
selected synthesized drugs are useful to counteract diﬀerent
demyelinating disorders such as multiple sclerosis (together
with the similar diseases called idiopathic inﬂammatory
demyelinating diseases), tranversesmyelitis, Devic’s disease,
Figure 2: High-magniﬁcation photomicrographs of LFB-stained
midbrain sections from ethidium bromide induced group (negative
control).
Figure 3: High-magniﬁcation photomicrographs of LFB-stained
midbrain sections from standard drug-treated group.
progressive multifocal leukoencephalopathy, optic neuri-
tis, Guillain-Barre syndrome and its chronic counterpart,
chronicinﬂammatorydemyelinatingpolyneuropathy,andso
forth which will be a great relief for our society to overcome
the above-said neurological disorders. The current paper
oﬀers compelling, but perhaps not conclusive, arguments
for an association between behavioral and brain anatomical
changes induced by EB and its attenuation by selected
synthesized quinoxaline dione derivatives.6 The Scientiﬁc World Journal
Figure 4: High-magniﬁcation photomicrographs of LFB-stained
midbrain sections from 4b-treated group.
Figure 5: High-magniﬁcation photomicrographs of LFB-stained
midbrain sections from 5b-treated group.
3.1. Experimental. All the solvents and materials were
reagent-gradedand puriﬁed as required. Melting points were
taken in open glass capillary using Veego VMP-1 melting
point apparatusandareuncorrected.IRspectrawererecord-
ed on Shimadzu FT-IR spectrometer model using KBr discs.
The NMR spectra (DMSO-d6)w e r er e c o r d e do nB r u k e r
DRX-300 spectrometer with TMS as an internal standard.
T h em a s ss p e c t r aw e r em e a s u r e do naS h i m a d z uL C M S
2010A spectrometer.
3.2. Synthesis of Quinoxaline-2, 3-Dione (2) under Thermal
Conditions. A powdered mixture of oxalic acid dihydrate
(0.01 mole, 1.26g) and o-phenylene diamine (0.01 mole,
1.0814g) was reﬂuxed by using an oil bath for 1.5 hours and
cooled. The product that separated was ﬁltered and washed
with water and recrystallized with 5% NaOH/dil HCl to give
the colourless crystals.
3.2.1. Under Microwave Irradiation. A powdered mixture of
oxalic acid dihydrate (0.01 mole, 1.26g) and o-phenylene
diamine(0.01mole,1.0814g)wasputinanopenbeaker,and
1mL of water added and mixed thoroughly. The mixture was
irradiatedinacatalystmicrowavesystematanemittedpower
of 400W for 3min. 100mL of water was added, followed
by further irradiation for 1min to give a clear solution
Figure 6: High-magniﬁcation photomicrographs of LFB-stained
midbrain sections from 5b-treated group.
and then left to stand at room temperature. The product
obtained was ﬁltered, washed with water, and crystallized
with 5% NaOH/dil HCl to give colourless crystals 2, (88%),
mp > 340◦C; Rf (chloroform/methanol 9:1) 0.52; IR (KBr):
1708.9 and 1681 (C=O), 1247 (C–N), 3344 (N–H), 854 (Ar
C–H), 1593 (C=C); 1H NMR (DMSO-d6,300 MHZ): δ 11.7
(s, 2H,N H ) ,7( m ,4H, Ar-H); ms (m/z): M+ calculated
162.15, found 161.98.
3.3. General Procedure for the Synthesis of Mannich Bases (2a–
c). A mixture of quinoxaline-2, 3-dione (0.01mol, 0.162
g m )i nD M F ,f o r m a l d e h y d e( 4 0 % ,1 . 5 m L )a n dd i ﬀerent
ketones (0.02mol) was stirred at room temperature for 6h.
The precipitated solid was ﬁltered under suction, washed
with ethanol and recrystallized from hot ethanol, to give
colourless crystals 2a–c.
3.3.1. 1,4-Bis(3-Oxobutyl) Quinoxaline-2,3(1H,4H)-Dione
(2a). Colourless crystals 2a, (70%), mp > 300◦C; Rf (ben-
zene/acetone 9:1) 0.23; IR (KBr): 1708.9 and 1681 (C=O),
1247.9 (C–N), 1473 (CH2); 1H NMR (DMSO-d6,300 MHZ):
δ 2.1(s,6H,C H3),3.3(m,4H,N –CH2–CH2),6.5–7(m ,4H,
Ar–H); ms (m/z): M+ calculated 302.15, found 301.98.
3.4. Ethidium-Bromide-Induced Model . Healthy, adult Wis-
ter rats of both sex male: female (1:1) weighing 120–140
gm were used which was approved by the Institutional
ethicalcommittee.Theanimalhousewaswellventilated,and
animals were kept at 12 ± 2◦C. The animals were caged in
large specious hygienic cages during the course of experi-
mental method. The animals were fed with rat pallet feed,
supplied by Hindustan Liver Pvt. Ltd. The place of ex-
periment to be conducted was kept in very hygienic condi-
tion.
This chemical is mainly used for local demyelination.
Here, demyelinating lesions were created in brain. For the
surgical procedure, the animals from both treatments were
anesthetized with ketamine chloridate and xylazine (5:1;
0.1mL/100gm),andaftersavingthefronto-parietal-occipital
area, antisepsis with 2% iodine solution was carried out.
With the aid of a roof motor of orthodontic use and a drillThe Scientiﬁc World Journal 7
number2,aholewasmade0.85cmtotherightofthebregma
until exposing the durameter. With the use of a Hamilton
syringe with a removable needle of caliber 26s, the solutions
were injected in the cistern pontis (basal), an enlargement
of the subarachnoid space on the ventral surface of the pons.
TenmicrolitresofEBwasinjectedtotheanimalsfromgroups
II to VII, and the same volume of 0.9% saline solution was
injected to the animals from group I. The durameter was
left open and the skin, together with the remainder of the
subcutaneous tissue, was sutured with a nylon thread 4.0 [8].
Fortheevaluationofcomparativeprotectiveeﬀectofsyn-
thesized drugs, selected doses were administered to animals
for 28 days after the inoculation of ethidium bromide.
The experimental design of the investigation was carried
out in seven groups among which the Gr-I and Gr-II were
having three animals each and from Gr-III to Gr-VII the
number of animals was ﬁve. The groupings were as follows:
Group I (three animals). Served as solvent control which re-
ceivedonly0.3%CMC(2mL)orallyandantioxidantin0.3%
CMC solution (2mL) once orally daily.
Group II (three animals). Received demyelinating agent ethi-
dium bromide (10μL solution of 0.1% ethidium bromide
in PBS) intracranially only once and 0.3% CMC solution
(2mL) once orally daily.
Group III (ﬁve animals). Received demyelinating agent ethi-
dium bromide (10μL solution of 0.1% ethidium bromide in
PBS) intracranially only once and antioxidant in 0.3% CMC
solution (2mL) once orally daily.
Group IV (ﬁve animals). Received demyelinating agent ethi-
dium bromide (10μL solution of 0.1% ethidium bromide
in PBS) intracranially only once and 2,3-dioxo-1,2,3,4-tetra-
hydroquinoxaline-6-sulphonyl (2-methyl) benzimidazole in
0.3% CMC solution (2mL) once orally daily.
Group V (ﬁve animals). Received demyelinating agent ethid-
ium bromide (10μL solution of 0.1% ethidium bromide in
PBS) intracranially only once and quinoxaline-2, 3-bis phen-
yl hydrazone 0.3% CMC solution (2mL) once orally daily.
Group VI (ﬁve animals). Received demyelinating agent ethi-
dium bromide (10μL solution of 0.1% ethidium bromide in
PBS)intracraniallyonlyonceand1,4-bis(3-oxobutyl)quin-
oxaline-2, 3(1H, 4H)-dione in 0.3% CMC solution (2mL)
once orally daily.
3.4.1. Methods of Testing
(i) Open-Field Exploratory Behavior Test. This test has been
utilized for behavioral changes in rodents to a novel environ-
ment and has been used to detect anxiogenic and anxiolytic
activity under identical situation. A typical apparatus suit-
able for rats comprises of large black area (96 × 96)cm with
height 96cm walls. The ﬂoor is divided into 16 squares by
white lines. The apparatus is placed in a dim light room. The
rats will be placed in a corner of the apparatus individually
and observed for 15–20min. The parameters are as follows.
(i) Ambulation: number of squares crossed by the ani-
mal in the apparatus.
(ii) Freeze: Periods of immobility, the time for which the
animal shows no movement.
(iii) Rearing: number of times when animal stands on its
rear paws.
(iv) Defecation: number of fecal pellets.
Since exposure to a novel environment is associated with
“emotionality”, an anxious animal is one which shows re-
duced ambulation associated with periodic “freeze” and
reduced normal behavior like growing, concomitant with
increased autonomic activity resulting in increase defecation
and urination accentuated by anxiogenic and anxiolytic
agent. Each animal was placed individually at one corner of
the apparatus and watched the above parameters for 15–20
minutes [9].
(ii) Grip Strength Test. This test is performed to access mus-
cular strength or neuromuscular function in rats which will
be inﬂuenced not only by sedative drugs and skeletal muscle
relaxant compounds but also by toxic agents. The method
was discovered as “test de” grippment by Boissler and Simon
(1960). The animals will be proposed to a horizontal thin
thread or metallic wire suspended about 10cm in the air,
which they immediately grasp with the fore limbs. Normal
animals are able to catch the wire with hind limbs and to
climb up with in 5sec. The animals that are not able to
touch the wire are considered as impaired. Each rat was
tested for grip strength. Parameters observed were the time
required to catch the wire with hind limb, time of falling,
time of immobility, and number of fecal pellets. The tests
were carried out for 5min for each animal [10].
(iii) Rota Rod Method. This test is used to evaluate the
activity of drugs interfering with motor coordination. In
1956, Paunam and Mixa suggested that the skeletal muscle
relaxant-induced by test compound can be evaluated by
testing the ability of rat to remain on a revolving rod. The
application consists of horizontal metal rod of 3cm diameter
attached to a motor with the speed 20–25rpm. The rod is
dividedinﬁvereactionswithwoodencompartment.Itallows
simultaneoustestingofﬁverats.Therodisinheightof50cm
above the table top in order to discourage the animal from
falling oﬀ.T h ec o m p a r t m e n tm a d ew i t hw o o d e nc a r d b o a r d
to restrict the escape of animals when they fall from the rod.
The test animals along with normal animals will be tested
for the time of falling from the roller, number of fecal pellets
and its behavior. The rats were placed on rotating rod, and
observations were made for the falling time, number of fecal
pellets, frequency of urination and its behaviour [11].
(iv) Beam Walk Test. This test is used to evaluate the activity
of the drugs interfering with motor coordination. In this8 The Scientiﬁc World Journal
test, the ability of animal to walk on the beam is evaluated.
The apparatus consists of a horizontal metal rod of 1cm
diameter which is evaporated by two-side stands at 30cm
height.Theanimalswerekeptinthecenteroftherodtoallow
walking on the beam. The parameters such as the number of
fecal pellets, distance of walk, time of immobility, and falling
time are evaluated. The animals were observed for 5min.
Each animal was placed in the center of the metal beam and
observed for ﬁve minutes for the parameters such as fall of
time, distance of walk, number of fecal pellets, freezing time
and its behaviour [11].
(v) Photoactometer Test. To study the locomotor activity
(CNS-depressant activity) of ethidium bromide and its
recovery by means of quinoxaline dione derivatives on rats,
photoactometer is mainly used. Most of the CNS-acting
drugs inﬂuence the loco motor activities in human and
animals. Demyelinating agents such as ethidium bromide act
as CNS depressant which decreases the loco motor activities.
In other words, loco motor activity can be an index of
wakefulness (alertness) of mental activity. The loco motor
activity (horizontal activity) can be easily measured using an
actophotometer which operates on photoelectric cell which
is connected in a circuit with a connector. When the beam of
light falling on the photo cell is cut oﬀ by the animal, a count
is recorded. An actophotometer may have square or round
area in which the animal moves. Both mice and rat can be
used for testing in the apparatus. The total number of cutoﬀ
was measured mechanically for ten minutes per animal, and
observations were made.
Theanimalssubjectedfortheabovetestswillbeobserved
on the 1st, 2nd, and 4th week, but open-ﬁeld exploratory
behaviourtestobservationwillbemadeonlyforthe1stweek.
3.4.2. Histopathological Studies. To conﬁrm the demyelina-
tion used in the model, three rats injected with saline (group
I), three rats injected with EB alone (group II), and three
rats from treated groups III to VII were used for histological
analysis of the lesion. The rats were perfused under deep
anesthesia with 10% buﬀered formaline via the left ventricle
at the end of the behavioural studies. Brain stem coronal
slices with the lesion were embedded in paraﬃn for routine
processing, and 10μm sections were produced and stained
with Luxol fast blue staining [12].
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